Crossmark

All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia

Crossref DOI link: https://doi.org/10.1016/j.htct.2023.06.006

Published Print: 2024-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Mirfakhraie, Reza

Dehaghi, Bentolhoda Kuhestani

Ghorbi, Mahmoud Dehghani

Ghaffari-Nazari, Haniyeh

Mohammadian, Mozhdeh

Salimi, Maryam

Ardakani, Maria Tavakoli

Parkhideh, Sayeh http://orcid.org/0000-0002-3140-3254
License Information

Text and Data Mining valid from 2024-04-01

Text and Data Mining valid from 2024-04-01

Version of Record valid from 2023-07-27
More Information

This article is maintained by: Elsevier

Article Title: All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia

Journal Title: Hematology, Transfusion and Cell Therapy

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.htct.2023.06.006

Content Type: article

Copyright: © 2023 Published by Elsevier España, S.L.U. on behalf of Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular.